BioCryst Pharmaceuticals (BCRX) Upgraded by Zacks Investment Research to Hold

BioCryst Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  BioCryst Pharmaceuticals Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More BioCryst Pharmaceuticals (BCRX) Upgraded by Zacks Investment Research to Hold